Status:

COMPLETED

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

Lead Sponsor:

Hospital San Carlos, Madrid

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Brief Summary

Hormone therapy is the primary treatment option for patients with HR+ HER2- breast cancer. Despite its activity, hormone therapy is associated with initial, or more frequently acquired, resistance aft...

Eligibility Criteria

Inclusion

  • 1\. Documented histologically confirmed breast cancer with ER and/or PgR positive and HER2 negative status.
  • 2\. Locally advanced or metastatic breast cancer not deemed amenable to curative surgery or curative radiation therapy
  • 3\. HR+/HER2-
  • HR+: ER+ or PR+ test before or up to 60 days after MBC diagnosis
  • HER2-: any HER2 negative test and the absence of a positive test (IHC positive 3+, FISH positive/amplified, Positive NOS) before or up to 60 days after MBC diagnosis
  • 4\. Female or male patients \> 18 years
  • 5\. Have received at least one dose of palbociclib
  • 6\. At least 2 document clinical visits
  • 7\. Treatment with palbociclib should have started from November 2017 to November 2019
  • 8\. Data from the clinical records should be available.
  • 9\. Patients must be able to understand and sign informed consent if alive.

Exclusion

  • 1\. Previous treatment with hormonal therapy, targeted therapy or chemotherapy for metastatic disease. Previous anticancer treatment for early breast cancer are allowed.
  • 2\. Treatment with palbociclib in clinical trial or compassionate use programs
  • 3\. HER2 + (IHC 3+ or FISH +) tumors in the most recent or previous biopsies
  • 4\. HR negative tumors in the most recent biopsy

Key Trial Info

Start Date :

July 31 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 8 2022

Estimated Enrollment :

815 Patients enrolled

Trial Details

Trial ID

NCT04874025

Start Date

July 31 2021

End Date

June 8 2022

Last Update

August 8 2022

Active Locations (36)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (36 locations)

1

Hospital Universitario Reina Sofía

Córdoba, Andalusia, Spain, 14004

2

Hospital Universitario Virgen de las Nieves

Granada, Andalusia, Spain, 18014

3

Hospital Universitario Virgen Macarena

Seville, Andalusia, Spain, 41009

4

Hospital Univesitario Virgen del Rocío

Seville, Andalusia, Spain, 41013

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer | DecenTrialz